Short Summary
Huawei Technologies appealed the rejection of its PCT National Phase patent application (No. 201947029757) by the Controller of Patents. The appellant argued that the objections raised in the Second Examination Report were effectively addressed through amendments, and the rejection was based on procedural grounds rather than merits. The High Court set aside the impugned order and remanded the matter for reconsideration.
Detailed Summary
This matter relates to a Patent dispute in Huawei Technologies Co vs The Controller Of Patents on 19 September, 2023 (Case No: P23192748) before the Madras High Court decided on 2023-09-19.
Huawei Technologies appealed the rejection of its PCT National Phase patent application (No. 201947029757) by the Controller of Patents. The appellant argued that the objections raised in the Second Examination Report were effectively addressed through amendments, and the rejection was based on procedural grounds rather than merits. The High Court set aside the impugned order and remanded the matter for reconsideration.
The court issued its ruling in accordance with statutory intellectual property guidelines and applicable legal principles, directing procedural or substantive relief based on the record presented.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Madras High Court. Understanding the court's reasoning in Huawei Technologies Co., Ltd vs The Controller of Patents is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Paulsons Beauty and Fashion Private LimitedvsSulthana Restaurant
The plaintiff, Paulsons Beauty and Fashion Private Limited, filed Original Applications seeking an interim injunction to restrain the respondent, Sulthana Restaurant, from passing off or infringing its registered trade mark 'SULTHAN'S BIRIYANI'. The defendant argued that the names were not deceptively similar, that they cater to different customer classes, and that the name 'SULTANA' is a common universal term. The Court dismissed the applications, finding no deceptive similarity and ruling in favor of the respondent.
Boehringer Ingelheim Pharma Gmbh And CovsThe Controller Of Patents & Anr.
Boehringer Ingelheim appealed against a single judge's decision regarding the maintainability of a revocation petition (CO (COMM. IPD-PAT) 38/2022). The core issues were whether a revocation petition could survive after the patentee pleaded invalidity in an infringement suit, or if it could continue after the patent expired by efflux of time.
M/S SNS PRODUCTS PRIVATE LIMITEDvsMohammed Naim
The Delhi High Court granted an ex-parte ad interim injunction in favor of M/S SNS Products Private Limited against Mohammed Naim. The plaintiff, a long-standing manufacturer of spices under the 'SHAN-E-DELHI' brand, sought protection against the defendant who was using substantially similar packaging and the mark 'Proud-ek-Minar'. The court found that the plaintiff had prima facie established their case for infringement, noting the similarity in trade dress and the defendant's prior purchase of the plaintiff's products. Consequently, the defendant is temporarily restrained from using the infringing materials and must disclose all existing inventory.
M/s.Vasanta Bhavan Hotels India Private LimitedvsPugal'n Vasanta Bhavan
M/s.Vasanta Bhavan Hotels India initiated a civil suit against Pugal'n Vasanta Bhavan alleging trademark infringement and passing off regarding the use of similar names in the hotel and food business. The plaintiff asserted extensive goodwill, long-standing usage since 1974, and registered trademarks for 'VASANTA BHAVAN.' Although the defendant was set ex parte, the court proceeded based on the plaintiff's evidence to address claims of deceptive similarity and irreparable harm.
Aratana Therapeutics, Inc.vsController of Patents and Designs
Aratana Therapeutics appealed the Controller's rejection of its patent application (No. 201747026233), which related to a weight-gaining compound for animals with chronic maladies. The appellant argued that their claims were limited to oral administration methods and did not claim a permanent cure, contrary to the Controller's interpretation under Section 3(i).
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.